Patents by Inventor Jonas VIKESAA

Jonas VIKESAA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230323421
    Abstract: The invention relates to antisense oligonucleotides which alter the splicing of XBP1 pre-mRNA. The antisense oligonucleotides have applications in enhancing the level and/or quality of protein expression in cells and in mammalian protein expression systems, such as heterologous protein expression systems, such as enhancing antibody expression in CHO cells. The antisense oligonucleotides also have applications in therapy, such as for the treatment or prevention of proteopathological diseases.
    Type: Application
    Filed: June 22, 2023
    Publication date: October 12, 2023
    Applicant: Roche Innovation Center Copenhagen A/S
    Inventors: Styliani TOURNAVITI, Jonas VIKESAA, Shan-Hua CHUNG
  • Publication number: 20230122753
    Abstract: The present invention relates to antisense oligonucleotides that are complementary to mammalian CD73 (NT5E) pre-mRNA, wherein the antisense oligonucleotides are capable of modulating the splicing of mammalian CD73 pre-mRNA exon 7. Splice modulation of mammalian CD73 exon 7 is beneficial for a range of medical disorders, including disorders in the field of immune-oncology.
    Type: Application
    Filed: August 26, 2022
    Publication date: April 20, 2023
    Inventors: Mads Aaboe JENSEN, Lars JOENSON, Gianluigi LICHINCHI, Jonas VIKESAA
  • Publication number: 20220160870
    Abstract: The invention relates to the field of immunotherapy and vaccine treatment of diseased cells via enhancing the immune response to the diseased cells. In the context of the present invention this is done by engineering neo-antigens in cells via oligonucleotide mediated production of aberrant RNA transcripts which, when transcribed in the cell, result in the generation or increased expression of aberrant polypeptides. Extracellular display of these polypeptides, of peptide fragments derived provides antigen epitopes (neoantigen) for detection by the immune system.
    Type: Application
    Filed: August 28, 2019
    Publication date: May 26, 2022
    Inventors: Troels Koch, Kamille Dumong Erichsen, Mads Jensen, Jonas Vikesaa, Lars Joenson, Klaus Jensen, Gianluigi Lichinchi
  • Publication number: 20220033818
    Abstract: The present invention relates to antisense oligonucleotides which are complementary to conserved TDP-43 binding sites on pre-mRNA transcripts, which are capable of restoring RNA binding protein function in the processing of multiple independent mRNAs in TDP-43 depleted cells.
    Type: Application
    Filed: July 23, 2021
    Publication date: February 3, 2022
    Inventors: Congwei WANG, Christian WEILE, Martin EBELING, Lars JOENSON, Jonas VIKESAA, Ravi JAGASIA, Meiling LI
  • Publication number: 20220002796
    Abstract: The invention relates to the field of therapeutic oligonucleotide analytics, and provides methods for primer based parallel sequencing of therapeutic oligonucleotides which provide sequence based quality information which may be used in conjunction with or in place of present chromatography or mass spectroscopic methods, and may be used, for example, in oligonucleotide therapeutic discovery, manufacture, quality assurance, therapeutic development, and patient monitoring.
    Type: Application
    Filed: May 6, 2019
    Publication date: January 6, 2022
    Applicant: Roche Innovation Center Copenhagen A/S
    Inventors: Mads JENSEN, Jonas VIKESAA, Lukasz KIELPINSKI, Lars JOENSON, Filippo SLADOJEVICH
  • Publication number: 20210269851
    Abstract: The invention relates to the field of therapeutic oligonucleotide analytics and discovery, and provides methods for primer based parallel sequencing of modified oligonucleotides which provide sequence based quality information which may be used in oligonucleotide therapeutic discovery, manufacture, quality assurance, therapeutic development, and patient monitoring.
    Type: Application
    Filed: May 6, 2019
    Publication date: September 2, 2021
    Applicant: Roche Innovation Center Copenhagen A/S
    Inventors: Mads JENSEN, Lars JOENSON, Lukasz KIELPINSKI, Jonas VIKESAA, Filippo SLADOJEVICH
  • Publication number: 20210071247
    Abstract: The invention relates to the field of therapeutic oligonucleotide analytics and discovery, and provides methods for primer based parallel sequencing of modified oligonucleotides which provide sequence based quality information which may be used in oligonucleotide therapeutic discovery, manufacture, quality assurance, therapeutic development, and patient monitoring.
    Type: Application
    Filed: May 6, 2019
    Publication date: March 11, 2021
    Applicant: Roche Innovation Center Copenhagen A/S
    Inventors: Mads JENSEN, Jonas VIKESAA, Lukasz KIELPINSKI, Lars JOENSON, Filippo SLADOJEVICH
  • Publication number: 20190284621
    Abstract: The present invention relates to the detection of therapeutic modified oligonucleotides in biological samples and an adaptor oligonucleotide (capture probe) which enables a quantitative PCR based detection method and the sequencing of modified oligonucleotides. The invention provides novel adaptor probes for use in detecting therapeutic oligonucleotides and for in vivo discovery of preferred therapeutic oligonucleotide sequences.
    Type: Application
    Filed: November 9, 2017
    Publication date: September 19, 2019
    Inventors: Mads Aaboe JENSEN, Lars JOENSON, Lukasz KIELPINSKI, Morten LINDOW, Jonas VIKESAA